These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31062064)

  • 1. A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure.
    Ullah S; Matzneller P; Zeitlinger M; Fuhr U; Taubert M
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Sep; 392(9):1097-1106. PubMed ID: 31062064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue pharmacokinetics of telavancin in healthy volunteers: a microdialysis study.
    Matzneller P; Österreicher Z; Reiter B; Lackner E; Stimpfl T; Zeitlinger M
    J Antimicrob Chemother; 2016 Nov; 71(11):3179-3184. PubMed ID: 27494910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation.
    Kidd JM; Sakon CM; Oleksiuk LM; Cies JJ; Pettit RS; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.
    Al Jalali V; Zeitlinger M
    Clin Pharmacokinet; 2018 Jul; 57(7):797-816. PubMed ID: 29332251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation.
    Lodise TP; Gotfried M; Barriere S; Drusano GL
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2300-4. PubMed ID: 18426898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus.
    Lepak AJ; Zhao M; Andes DR
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches.
    Barbour AM; Schmidt S; Zhuang L; Rand K; Derendorf H
    Int J Antimicrob Agents; 2014 Jan; 43(1):60-7. PubMed ID: 24183800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.
    Minichmayr IK; Schaeftlein A; Kuti JL; Zeitlinger M; Kloft C
    Clin Pharmacokinet; 2017 Jun; 56(6):617-633. PubMed ID: 27753002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects.
    Wong SL; Barriere SL; Kitt MM; Goldberg MR
    J Antimicrob Chemother; 2008 Oct; 62(4):780-3. PubMed ID: 18586659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects.
    Bunnell KL; Pai MP; Sikka M; Bleasdale SC; Wenzler E; Danziger LH; Rodvold KA
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29311094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
    Gotfried MH; Shaw JP; Benton BM; Krause KM; Goldberg MR; Kitt MM; Barriere SL
    Antimicrob Agents Chemother; 2008 Jan; 52(1):92-7. PubMed ID: 17923490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis.
    Burkhardt O; Brunner M; Schmidt S; Grant M; Tang Y; Derendorf H
    J Antimicrob Chemother; 2006 Sep; 58(3):632-6. PubMed ID: 16840426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
    Barbour A; Schmidt S; Sabarinath SN; Grant M; Seubert C; Skee D; Murthy B; Derendorf H
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2773-6. PubMed ID: 19364847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy.
    Bue M; Sou T; Okkels ASL; Hanberg P; Thorsted A; Friberg LE; Andersson TL; Öbrink-Hansen K; Christensen S
    Int J Infect Dis; 2020 Mar; 92():133-140. PubMed ID: 31978581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis.
    Brill MJ; Houwink AP; Schmidt S; Van Dongen EP; Hazebroek EJ; van Ramshorst B; Deneer VH; Mouton JW; Knibbe CA
    J Antimicrob Chemother; 2014 Mar; 69(3):715-23. PubMed ID: 24214905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis.
    Autry EB; Rybak JM; Leung NR; Gardner BM; Burgess DR; Anstead MI; Kuhn RJ
    Pharmacotherapy; 2016 Jan; 36(1):13-8. PubMed ID: 26748559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.
    Ulldemolins M; Roberts JA; Wallis SC; Rello J; Lipman J
    J Antimicrob Chemother; 2010 Aug; 65(8):1771-8. PubMed ID: 20530507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetic Modeling and Probability of Target Attainment of Ceftaroline in Brain and Soft Tissues.
    Helfer VE; Zavascki AP; Zeitlinger M; de Araújo BV; Dalla Costa T
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0074122. PubMed ID: 36005769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function.
    Lodise TP; Butterfield JM; Hegde SS; Samara E; Barriere SL
    Antimicrob Agents Chemother; 2012 Apr; 56(4):2062-6. PubMed ID: 22252799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue penetration of telavancin after intravenous administration in healthy subjects.
    Sun HK; Duchin K; Nightingale CH; Shaw JP; Seroogy J; Nicolau DP
    Antimicrob Agents Chemother; 2006 Feb; 50(2):788-90. PubMed ID: 16436747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.